- Home
- CLW vs OPT Comparison
CLW vs OPT Comparison
Compare CLW & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- OPT
- Stock Information
- Founded
- CLW 2005
- OPT 1984
- Country
- CLW United States
- OPT Australia
- Employees
- CLW N/A
- OPT N/A
- Industry
- CLW Paper
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLW Basic Materials
- OPT Health Care
- Exchange
- CLW Nasdaq
- OPT Nasdaq
- Market Cap
- CLW 501.0M
- OPT 574.0M
- IPO Year
- CLW N/A
- OPT 2020
- Fundamental
- Price
- CLW $31.02
- OPT $4.41
- Analyst Decision
- CLW Buy
- OPT Strong Buy
- Analyst Count
- CLW 1
- OPT 1
- Target Price
- CLW $37.00
- OPT $12.00
- AVG Volume (30 Days)
- CLW 534.1K
- OPT 19.4K
- Earning Date
- CLW 02-18-2025
- OPT 02-26-2025
- Dividend Yield
- CLW N/A
- OPT N/A
- EPS Growth
- CLW N/A
- OPT N/A
- EPS
- CLW 0.88
- OPT N/A
- Revenue
- CLW $2,211,900,000.00
- OPT $261,859.00
- Revenue This Year
- CLW N/A
- OPT N/A
- Revenue Next Year
- CLW N/A
- OPT $46,864.26
- P/E Ratio
- CLW $257.11
- OPT N/A
- Revenue Growth
- CLW 58.65
- OPT N/A
- 52 Week Low
- CLW $23.97
- OPT $1.79
- 52 Week High
- CLW $57.13
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- CLW 62.69
- OPT 66.30
- Support Level
- CLW $28.11
- OPT $3.59
- Resistance Level
- CLW $30.71
- OPT $3.90
- Average True Range (ATR)
- CLW 1.22
- OPT 0.26
- MACD
- CLW 0.06
- OPT 0.06
- Stochastic Oscillator
- CLW 89.80
- OPT 100.00
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.